Dendreon: Anticancer Immunotherapy, Reimbursement, and New Promises

This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.

Read more »

BREAKING: Opexa Initiates Late Stage Clinical Study of Tcelna in Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Opexa Therapeutics, Inc. today announced the initiation of a Phase IIb clinical trial of Tcelna™, a novel T-cell therapy for multiple sclerosis (MS), in patients with Secondary Progressive Multiple Sclerosis (SPMS). The therapy is specifically tailored to each patient’s individual disease profile and has demonstrated superior safety and encouraging indications of efficacy in previous clinical studies in MS that included the treatment of SPMS patients.

Read more »

Bulls, Bears: 3 Promising Stocks in Metastatic Cancer

In this special series, we explore the state of select public companies operating in a particularly intriguing area of life sciences. This week, we look at metastatic cancer, an area of significant unmet need. These companies, including OncoSec Medical, are having success with their innovative approaches to treating metastatic cancer, and are seeing results in their performance int he public markets.

Read more »

The Briefing Room, September 5: Today in Microcap Biotech Stocks

OneMedPlace introduces a new series, “The Briefing Room”, capturing the most important developments in microcap life sciences indexes. This week, we focus on three interesting developments in oncology, and a special bonus!

Read more »

Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results

Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.

Read more »

IMUC: Immunotherapy On Multiple Fronts

In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.

Read more »

Quantum Immunologics’ Alternative to Chemotherapy

The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.

Read more »

For Advaxis, Bacteria Help More Than They Hurt

The idea of using harmful bacteria to treat disease might strike many as an odd concept.

Read more »

Provenge Extends Life of Prostate Cancer Patients, Study Finds

Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.

Read more »

[Video Profile] Inovio Biomedical Corporation

Solid tumors represent 85 percent of all cancers, creating a huge clinical need for localized, site-specific cancer treatment. Inovio Medical Corporation of San Diego is developing DNA-based vaccines that harness the body’s immune system to prevent and treat chronic diseases such as cancer and HIV.

Read more »